{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:44Z","timestamp":1740107684321,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10067-022-06390-x","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T16:04:28Z","timestamp":1664208268000},"page":"721-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-2224","authenticated-orcid":false,"given":"Hiroya","family":"Tamai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Otomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"1","key":"6390_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/art.21548","volume":"54","author":"S \u00d8deg\u00e5rd","year":"2006","unstructured":"\u00d8deg\u00e5rd S, Landew\u00e9 R, van der Heijde D, Kvien TK, Mowinckel P, Uhlig T (2006) Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 54(1):68\u201375. https:\/\/doi.org\/10.1002\/art.21548","journal-title":"Arthritis Rheum"},{"issue":"7","key":"6390_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19(7):822\u2013824. https:\/\/doi.org\/10.1038\/nm.3260","journal-title":"Nat Med"},{"issue":"22","key":"6390_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/nejm200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594\u20131602. https:\/\/doi.org\/10.1056\/nejm200011303432202","journal-title":"N Engl J Med"},{"issue":"9","key":"6390_CR4","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162\u20131167. https:\/\/doi.org\/10.1136\/ard.2006.068064","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6390_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Westhovens R (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144(12):865\u2013876. https:\/\/doi.org\/10.7326\/0003-4819-144-12-200606200-00003","journal-title":"Ann Intern Med"},{"issue":"9","key":"6390_CR6","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1359\/jbmr.090320","volume":"24","author":"NC Walsh","year":"2009","unstructured":"Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24(9):1572\u20131585. https:\/\/doi.org\/10.1359\/jbmr.090320","journal-title":"J Bone Miner Res"},{"issue":"12","key":"6390_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/jci11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106(12):1481\u20131488. https:\/\/doi.org\/10.1172\/jci11176","journal-title":"J Clin Invest"},{"issue":"6","key":"6390_CR8","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","volume":"169","author":"P Palmqvist","year":"2002","unstructured":"Palmqvist P, Persson E, Conaway HH, Lerner UH (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169(6):3353\u20133362. https:\/\/doi.org\/10.4049\/jimmunol.169.6.3353","journal-title":"J Immunol"},{"issue":"11","key":"6390_CR9","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2007.080713","volume":"67","author":"R Axmann","year":"2008","unstructured":"Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67(11):1603\u20131609. https:\/\/doi.org\/10.1136\/ard.2007.080713","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6390_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156\u2013163. https:\/\/doi.org\/10.1038\/nm1538","journal-title":"Nat Med"},{"issue":"4","key":"6390_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00774-013-0514-1","volume":"32","author":"S Kaneshiro","year":"2014","unstructured":"Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M, Hashimoto J (2014) IL-6 negatively regulates osteoblast differentiation through the SHP2\/MEK2 and SHP2\/Akt2 pathways in vitro. J Bone Miner Metab 32(4):378\u2013392. https:\/\/doi.org\/10.1007\/s00774-013-0514-1","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"6390_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6390_CR13","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6390_CR14","first-page":"743","volume":"26","author":"D van der Heijde","year":"1999","unstructured":"van der Heijde D (1999) How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol 26(3):743\u2013745","journal-title":"J Rheumatol"},{"issue":"2","key":"6390_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cyto.2015.04.011","volume":"75","author":"M Takeshita","year":"2015","unstructured":"Takeshita M, Suzuki K, Kikuchi J, Izumi K, Kurasawa T, Yoshimoto K, Takeuchi T (2015) Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. Cytokine 75(2):222\u2013227. https:\/\/doi.org\/10.1016\/j.cyto.2015.04.011","journal-title":"Cytokine"},{"issue":"6611","key":"6390_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/385081a0","volume":"385","author":"F Austrup","year":"1997","unstructured":"Austrup F, Vestweber D, Borges E, L\u00f6hning M, Br\u00e4uer R, Herz U, Hamann A (1997) P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 385(6611):81\u201383. https:\/\/doi.org\/10.1038\/385081a0","journal-title":"Nature"},{"issue":"7","key":"6390_CR17","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/art.1780390702","volume":"39","author":"PP Tak","year":"1996","unstructured":"Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39(7):1077\u20131081. https:\/\/doi.org\/10.1002\/art.1780390702","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6390_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/rheumatology\/keh437","volume":"44","author":"D Aeberli","year":"2005","unstructured":"Aeberli D, Seitz M, J\u00fcni P, Villiger PM (2005) Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford) 44(2):172\u2013175. https:\/\/doi.org\/10.1093\/rheumatology\/keh437","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"6390_CR19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Maini RN (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163(3):1521\u20131528","journal-title":"J Immunol"},{"issue":"11","key":"6390_CR20","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/jci36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118(11):3537\u20133545. https:\/\/doi.org\/10.1172\/jci36389","journal-title":"J Clin Invest"},{"issue":"10","key":"6390_CR21","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/eji.1830211039","volume":"21","author":"C Haworth","year":"1991","unstructured":"Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21(10):2575\u20132579. https:\/\/doi.org\/10.1002\/eji.1830211039","journal-title":"Eur J Immunol"},{"issue":"4","key":"6390_CR22","first-page":"225","volume":"6","author":"DM Butler","year":"1995","unstructured":"Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6(4):225\u2013230","journal-title":"Eur Cytokine Netw"},{"issue":"8657","key":"6390_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/s0140-6736(89)90430-3","volume":"2","author":"FM Brennan","year":"1989","unstructured":"Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2(8657):244\u2013247. https:\/\/doi.org\/10.1016\/s0140-6736(89)90430-3","journal-title":"Lancet"},{"issue":"10","key":"6390_CR24","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10):3959\u20133964. https:\/\/doi.org\/10.1182\/blood-2008-05-155846","journal-title":"Blood"},{"issue":"1","key":"6390_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/annrheumdis-2011-200348","volume":"71","author":"MH Wenink","year":"2012","unstructured":"Wenink MH, Santegoets KC, Platt AM, van den Berg WB, van Riel PL, Garside P, McInnes IB (2012) Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. Ann Rheum Dis 71(1):80\u201383. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200348","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6390_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.37787","volume":"65","author":"M Bonelli","year":"2013","unstructured":"Bonelli M, Ferner E, G\u00f6schl L, Bl\u00fcml S, Hladik A, Karonitsch T, Scheinecker C (2013) Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum 65(3):599\u2013607. https:\/\/doi.org\/10.1002\/art.37787","journal-title":"Arthritis Rheum"},{"issue":"8","key":"6390_CR27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-009-1107-7","volume":"21","author":"IC Chang","year":"2010","unstructured":"Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21(8):1401\u20131409. https:\/\/doi.org\/10.1007\/s00198-009-1107-7","journal-title":"Osteoporos Int"},{"issue":"1","key":"6390_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1091\/mbc.e02-06-0354","volume":"14","author":"MA Chellaiah","year":"2003","unstructured":"Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Hruska KA (2003) Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14(1):173\u2013189. https:\/\/doi.org\/10.1091\/mbc.e02-06-0354","journal-title":"Mol Biol Cell"},{"issue":"3","key":"6390_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/ard.2007.076604","volume":"67","author":"F Chopin","year":"2008","unstructured":"Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67(3):353\u2013357. https:\/\/doi.org\/10.1136\/ard.2007.076604","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6390_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00774-013-0535-9","volume":"32","author":"T Okano","year":"2014","unstructured":"Okano T, Koike T, Tada M, Sugioka Y, Mamoto K, Wakitani S, Nakamura H (2014) The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid. J Bone Miner Metab 32(5):593\u2013600. https:\/\/doi.org\/10.1007\/s00774-013-0535-9","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"6390_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65(11):1495\u20131499. https:\/\/doi.org\/10.1136\/ard.2005.044198","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6390_CR32","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","volume":"44","author":"U Lange","year":"2005","unstructured":"Lange U, Teichmann J, M\u00fcller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44(12):1546\u20131548. https:\/\/doi.org\/10.1093\/rheumatology\/kei082","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"6390_CR33","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/ar2219","volume":"9","author":"H Marotte","year":"2007","unstructured":"Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9(3):R61. https:\/\/doi.org\/10.1186\/ar2219","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"6390_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","volume":"43","author":"AC Bay-Jensen","year":"2014","unstructured":"Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA (2014) Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum 43(4):470\u2013478. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.07.008","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"6390_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, Platt A (2012) IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 42(2):131\u2013139. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.01.004","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"6390_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"P Garnero","year":"2010","unstructured":"Garnero P, Thompson E, Woodworth T, Smolen JS (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62(1):33\u201343. https:\/\/doi.org\/10.1002\/art.25053","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6390_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briot","year":"2015","unstructured":"Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, Roux C (2015) The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine 82(2):109\u2013115. https:\/\/doi.org\/10.1016\/j.jbspin.2014.10.015","journal-title":"Joint Bone Spine"},{"issue":"12","key":"6390_CR38","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41590-019-0526-7","volume":"20","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, Ishii M (2019) Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol 20(12):1631\u20131643. https:\/\/doi.org\/10.1038\/s41590-019-0526-7","journal-title":"Nat Immunol"},{"issue":"5","key":"6390_CR39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s8756-3282(01)00420-3","volume":"28","author":"M Komine","year":"2001","unstructured":"Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O (2001) Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 28(5):474\u2013483. https:\/\/doi.org\/10.1016\/s8756-3282(01)00420-3","journal-title":"Bone"},{"doi-asserted-by":"publisher","unstructured":"Yao Z, Getting SJ, and Locke IC (2021) Regulation of TNF-Induced Osteoclast Differentiation. Cells 11(1):132. https:\/\/doi.org\/10.3390\/cells11010132","key":"6390_CR40","DOI":"10.3390\/cells11010132"},{"issue":"1","key":"6390_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.38218","volume":"66","author":"K Yokota","year":"2014","unstructured":"Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, Mimura T (2014) Combination of tumor necrosis factor \u03b1 and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 66(1):121\u2013129. https:\/\/doi.org\/10.1002\/art.38218","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"6390_CR42","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","volume":"47","author":"M Hashizume","year":"2008","unstructured":"Hashizume M, Hayakawa N, Mihara M (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 47(11):1635\u20131640. https:\/\/doi.org\/10.1093\/rheumatology\/ken363","journal-title":"Rheumatology (Oxford)"},{"issue":"27","key":"6390_CR43","doi-asserted-by":"publisher","first-page":"19301","DOI":"10.1074\/jbc.274.27.19301","volume":"274","author":"CA O'Brien","year":"1999","unstructured":"O\u2019Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC (1999) STAT3 activation in stromal\/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 274(27):19301\u201319308. https:\/\/doi.org\/10.1074\/jbc.274.27.19301","journal-title":"J Biol Chem"},{"doi-asserted-by":"publisher","unstructured":"Adam S, Simon N, Steffen U, Andes FT, Scholtysek C, M\u00fcller DI H, Hueber AJ (2020) JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med 12(530):eaay4447. https:\/\/doi.org\/10.1126\/scitranslmed.aay4447","key":"6390_CR44","DOI":"10.1126\/scitranslmed.aay4447"},{"issue":"9","key":"6390_CR45","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2018-214894","volume":"78","author":"S Finzel","year":"2019","unstructured":"Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J, Schett G (2019) Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis 78(9):1186\u20131191. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214894","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6390_CR46","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2011-201075","volume":"72","author":"S Finzel","year":"2013","unstructured":"Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Schett G (2013) Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis 72(3):396\u2013400. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201075","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6390_CR47","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1136\/ard.2008.097048","volume":"68","author":"U M\u00f8llerD\u00f8hn","year":"2009","unstructured":"M\u00f8llerD\u00f8hn U, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A, \u00d8stergaard M (2009) Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 68(10):1585\u20131590. https:\/\/doi.org\/10.1136\/ard.2008.097048","journal-title":"Ann Rheum Dis"},{"issue":"52","key":"6390_CR48","doi-asserted-by":"publisher","first-page":"20764","DOI":"10.1073\/pnas.0805133106","volume":"105","author":"L Pederson","year":"2008","unstructured":"Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ (2008) Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 105(52):20764\u201320769. https:\/\/doi.org\/10.1073\/pnas.0805133106","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06390-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T09:05:35Z","timestamp":1676538335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06390-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6390"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06390-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Tamai received honoraria from AbbVie and Eisai. Dr. Kikuchi received honoraria from Bristol Myers Squibb, Chugai and Mitsubishi-Tanabe. Dr. Izumi received honoraria from AbbVie, Asahi-Kasei, Ayumi, Bristol Myers Squibb, Chugai, Eisai and Eli Lilly. Dr. Otomo received honoraria from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Eli Lilly, Glaxo SmithKline, Jansen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi and UCB. Dr. Yamaoka received honoraria from Pfizer, Chugai Pharma, Takeda Industrial Pharma, Astellas Pharma, Abbvie, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma, GlaxoSmithkline, Eli Lilly, Janssen Pharma, Eisai Pharma, Actelion Pharmaceuticals Japan, Asahikasei Pharma Corp, Ono Pharma, Otsuka Pharma, Nippon Shinyaku, Gilead G.K, Daiichi Sankyo, Boehringer Ingelheim Japan, Japan Tobacco Inc., Hisamitsu Pharma Co, MSD, Sanofi, AYUMI Pharma Co, and Nippon Kayaku. Dr. Takeuchi received honoraria from Astellas, AbbVie, Ayumi, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Mitsubishi-Tanabe, Nippon-kayaku, Novartis, Pfizer, Sanofi, UCB and research support from Asahi Kasei, AbbVie, Ayumi, Boehringer-Ingelheim, Chugai, Eisai, Eli Lilly, Mitsubishi-Tanabe, Sanofi, and UCB. Dr. Kaneko received honoraria from Asahi Kasei, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Eisai, Elli Lilly, Mitsubishi-Tanabe, Novartis, UCB, and research support from AbbVie, Chugai, Eisai, Mitsubishi-Tanabe, and UCB. The other authors declare no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}